Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757013 | 0.88 | USP30 (0.39) | USP30P2RX7GPR183SCD5NR1H2 | |
| SCHEMBL19693266 | 0.84 | SCD5 (0.42) | USP30GPR183SCD5NR1H2ACACB | |
| SCHEMBL23584405 | 0.81 | USP30 (0.40) | USP30GPR183SCD5ACACBCYP11B2 | |
| SCHEMBL21060289 | 0.81 | USP30 (0.38) | USP30P2RX7GPR183SCD5NR1H2 | |
| SCHEMBL23931390 | 0.79 | USP30 (0.41) | USP30GPR183NR1H2RORCUSP2 | |
| SCHEMBL520363 | 0.78 | USP30 (0.42) | USP30P2RX7NR1H2USP2SMN1; SMN2 | |
| SCHEMBL10179664 | 0.77 | P2RX7 (0.46) | USP30P2RX7NR1H2USP2SMN1; SMN2 | |
| SCHEMBL26134743 | 0.76 | SCD5 (0.42) | USP30P2RX7GPR183SCD5NR1H2 | |
| SCHEMBL30051523 | 0.76 | P2RX7 (0.44) | USP30P2RX7NR1H2USP2SMN1; SMN2 | |
| SCHEMBL23931417 | 0.76 | USP30 (0.39) | USP30P2RX7GPR183SCD5NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674484-A2 | THIENOPYRROLE COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4291562-B1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4291562-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022173722-A1 | THIENOPYRROLE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217990-A1 | THIENOPYRROLE COMPOUNDS | SSB, TPMT, LCP2 | USP30 4555/4885P2RX7 291/4885GPR183 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.